Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes

Gynecologic Oncology

Volumn 137, Issue 1, 2015, Pages 55-59

  Verhoef, Viola M J ^a,d   Van Kemenade, Folkert J ^b   Rozendaal, Lawrence ^a   Heideman, Daniëlle A M ^a   Bosgraaf, Remko P ^c   Hesselink, Albertus T ^a   Melchers, Willem J G ^c   Massuger, Leon F A G ^c   Bekkers, Ruud L M ^c   Steenbergen, Renske D M ^a   Berkhof, Johannes ^a   Snijders, Peter J F ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Cervical intraepithelial neoplasia; Cervical scrape; Cervical screening; Cytology; DNA methylation; Human papillomavirus; Triage

Indexed keywords

ADULT; ARTICLE; CADM1 MAL METHYLATION ASSAY; COLPOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE EXPRESSION ASSAY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; METHYLATION; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; ALPHAPAPILLOMAVIRUS; CONTROLLED STUDY; DNA METHYLATION; EMERGENCY HEALTH SERVICE; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; MAL PROTEIN, HUMAN; MYELIN AND LYMPHOCYTE PROTEIN; TUMOR MARKER;

ADULT; ALPHAPAPILLOMAVIRUS; CELL ADHESION MOLECULES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA METHYLATION; FEMALE; HUMANS; IMMUNOGLOBULINS; MIDDLE AGED; MYELIN AND LYMPHOCYTE-ASSOCIATED PROTEOLIPID PROTEINS; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; TRIAGE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84929940746     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.01.550     Document Type: Article

References (32)

1. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13(1):78-88.
2. Naucler P, RydW, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101(2):88-99.
3. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquidbased cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10(7):672-82.
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11(3):249-57.
5. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119(5):1095-101.
6. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100(7):492-501.
7. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130(3):602-10.
8. Dijkstra MG, van Niekerk D, Rijkaar DC, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen positive women? A POBASCAM trial sub study. Cancer Epidemiol Biomarkers Prev Jan 2014;23(1):55-63.
9. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013;17(5 Suppl 1):S28-35.
10. Castle PE, StolerMH, Wright Jr TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12(9):880-90.
11. Wright Jr TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206(1):46.
12. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97(14):1072-9.
13. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55(4):244-65.
14. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-27.
15. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112(2):293-9.
16. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 andMAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011;17(8):2459-65.
17. Overmeer RM, Louwers JA, Meijer CJ, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPVpositive women. Int J Cancer 2011;129(9):2218-25.
18. Bierkens M, Hesselink AT, Meijer CJ, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013;133(6):1293-9.
19. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)- genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14(6):395-405.
20. Verhoef VM, Bosgraaf RP, van Kemenade FJ, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014;15(3):315-22.
21. Verhoef VM, Dijkstra MG, Bosgraaf RP, et al. A second generation cervico-vaginal lavage device shows similar performance as its preceding version with respect to DNA yield and HPV DNA results. BMC Womens Health 2013;13:21.
22. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004;57(4):388-93.
23. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007;29(1):19-24.
24. De Strooper LM, Hesselink BA, Berkhof J, et al. Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol Biomarkers Prev June 2014;24.
25. De Strooper LM, van Zummeren M, Steenbergen RD, Bleeker MC, Hesselink AT, Wisman GB, Snijders PJ, Heideman DA, Meijer CJ. CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol Oct 2014;3.
26. Gok M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screeningmethod forwomenwho do not attend cervical screening: cohort study. BMJ 2010;340:c1040.
27. Gok M, van Kemenade FJ, Heideman DA, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer 2012;130(5):1128-35.
28. Bosgraaf RP, Verhoef VM, Massuger LF, et al. Comparative performance of novel selfsampling methods in detecting high-risk human papillomavirus in 30, 130 women not attending cervical screening. Int J Cancer 2015;136(3):646-55.
29. Thomas LK, Bermejo JL, Vinokurova S, et al. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract - a systematic review and meta-analysis. Eur J Cancer 2014;50(1):85-98.
30. Bierkens M, Wilting SM, van Wieringen WN, et al. Chromosomal profiles of highgrade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. Int J Cancer 2012;131(4):E579-85.
31. Bosgraaf RP, Mast PP, der Zanden PH Struik-van, Bulten J, Massuger LF, Bekkers RL. Overtreatment in a see-and-treat approach to cervical intraepithelial lesions. Obstet Gynecol 2013;121:1209-16.
32. Hopman EH, Kenemans P, Helmerhorst TJ. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv 1998;53:97-106.